Table 1. Baseline characteristics of the 2484 patients with tuberculosis according to the occurrence of severe adverse events due to pyrazinamide.
| Variables | Total | Serious adverse events due to PZA | P value | |
|---|---|---|---|---|
| N = 2478 | (‒), N = 2251 | (+), N = 227 | ||
| Age (year) | 49.6±18.4 | 49.0±18.3 | 55.5±18.5 | <0.001 |
| Sex, male (%) | 1319 (53.2) | 1048 (46.6) | 111 (48.9) | 0.500 |
| Tuberculosis | 0.291 | |||
| Pulmonary | 2102 (84.8) | 1904 (84.6) | 198 (87.2) | |
| Extrapulmonary | 376 (15.2) | 347 (15.4) | 29 (12.8) | |
| Initial diagnosis | 0.524 | |||
| Sputum AFB | 791 (33.7) | 722 (33.9) | 69 (31.8) | |
| TB-PCR | 1553 (66.3) | 1405 (66.1) | 148 (68.2) | |
| Comorbidities | ||||
| DM | 244 (9.8) | 214 (9.5) | 30 (13.2) | 0.074 |
| Malignancy | 133 (5.4) | 117 (5.2) | 16 (7.0) | 0.238 |
| Renal insufficiency | 26 (1.0) | 20 (1.0) | 4 (1.8) | 0.291 |
| Smokinga | 0.718 | |||
| Never | 1069 (56.8) | 871 (56.6) | 198 (57.7) | |
| Ex- or current | 814 (43.2) | 669 (43.4) | 145 (42.3) | |
| Alcohol useb | 0.553 | |||
| Never/social | 618 (89.7) | 473 (89.2) | 145 (91.2) | |
| Heavy | 71 (10.3) | 57 (10.8) | 14 (8.8) | |
| Long-term steroid use | 4 (0.2) | 4 (0.2) | 0 (0.0) | 1.000 |
| Risk factors for hepatotoxicity | ||||
| HBs Ag (+) | 57 (4.2) | 51 (4.2) | 6 (4.0) | 0.912 |
| Anti HCV (+) | 12 (0.9) | 12 (1.0) | 0 (0.0) | 0.381 |
| Initial laboratory tests | ||||
| AST | 22.0±11.8 | 21.8±11.1 | 24.2±16.8 | 0.090 |
| ALT | 19.4±14.6 | 19.4±14.8 | 19.6±13.5 | 0.881 |
| Treatment duration (mo.) | 8.0±3.1 | 7.9±3.1 | 9.2±3.4 | <0.001 |
AFB, acid-fast blue; TB, tuberculosis; PCR, polymerase chain reaction; DM, diabetes mellitus;
aData were not recorded for 595 (24.0%) patients.
bData were not recorded for 1789 (72.2%) patients.
Data are reported as the mean ± standard deviation and numbers (%).